Heron Therapeuti (HRTX)

Currency in USD
1.315
-0.525(-28.53%)
Closed·
After Hours
1.400+0.080(+6.06%)
·
HRTX Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Unusual Post-Market activity
Unusual trading volume
HRTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2301.460
52 wk Range
1.0402.680
Key Statistics
Prev. Close
1.84
Open
1.44
Day's Range
1.23-1.46
52 wk Range
1.04-2.68
Volume
14.79M
Average Volume (3m)
1.49M
1-Year Change
-8%
Book Value / Share
-0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HRTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.250
Upside
+375.29%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Heron Therapeuti News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Heron Therapeuti Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Heron Therapeuti Earnings Call Summary for Q2/2025

  • Heron Therapeutics missed Q2 2025 EPS (-0.02 USD vs -0.01 USD expected) and revenue ($37.2M vs $38.08M forecast), stock dropped 21.2% pre-market
  • Company transitioned to net income YTD despite quarterly miss; gross profit margin increased to 73.5% from 70.8% in previous quarter
  • Maintained net revenue guidance of $153-163M for the year, revised adjusted EBITDA guidance to $9-13M; expects inventory normalization in Q3
  • CEO highlighted strategy execution and financial strengthening; COO noted sales force optimization and creation of dedicated teams for key products
  • Analysts questioned Zenerlef 400mg transition impact and J-code reimbursement benefits; company addressed inventory adjustments and sales restructuring
Last Updated: 08/08/2025, 15:28
Read Full Transcript

Compare HRTX to Peers and Sector

Metrics to compare
HRTX
Peers
Sector
Relationship
P/E Ratio
−35.9x−0.4x−0.5x
PEG Ratio
−0.40−0.010.00
Price/Book
−9.8x2.7x2.6x
Price / LTM Sales
1.9x8.7x3.3x
Upside (Analyst Target)
226.1%318.4%43.4%
Fair Value Upside
Unlock7.1%7.1%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.250
(+375.29% Upside)

Earnings

Latest Release
Aug 08, 2025
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
37.20M / 38.08M
EPS Revisions
Last 90 days

HRTX Income Statement

People Also Watch

2.840
ABSI
-2.74%
11.97
CDNA
-0.83%
7.140
BBAI
+8.02%
3.44
ALT
-2.27%
16.41
VRDN
-0.73%

FAQ

What Stock Exchange Does Heron Therapeuti Trade On?

Heron Therapeuti is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Heron Therapeuti?

The stock symbol for Heron Therapeuti is "HRTX."

What Is the Heron Therapeuti Market Cap?

As of today, Heron Therapeuti market cap is 280.72M.

What Is Heron Therapeuti's Earnings Per Share (TTM)?

The Heron Therapeuti EPS (TTM) is -0.05.

When Is the Next Heron Therapeuti Earnings Date?

Heron Therapeuti will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is HRTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Heron Therapeuti Stock Split?

Heron Therapeuti has split 2 times.

How Many Employees Does Heron Therapeuti Have?

Heron Therapeuti has 122 employees.

What is the current trading status of Heron Therapeuti (HRTX)?

As of 08 Aug 2025, Heron Therapeuti (HRTX) is trading at a price of 1.32, with a previous close of 1.84. The stock has fluctuated within a day range of 1.23 to 1.46, while its 52-week range spans from 1.04 to 2.68.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.